ArticleGenome biology2008
Modified cell cycle status in a mouse model of altered neuronal vulnerability (slow Wallerian degeneration; Wlds).
Article in Genome biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Article
- UBA1: At the Crossroads of Ubiquitin Homeostasis and Neurodegeneration.Trends in molecular medicine · 2015Review
- Production and characterization of polyclonal antibody against a synthetic peptide from β-actin protein.Iranian journal of basic medical sciences · 2014Article
- Concepts for regulation of axon integrity by enwrapping glia.Frontiers in cellular neuroscience · 2013Review
- Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting.PloS one · 2013Article
- Retinal ganglion cell survival and axon regeneration in WldS transgenic rats after optic nerve crush and lens injury.BMC neuroscience · 2012Article
- WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity.Molecular neurodegeneration · 2012Article
- Article
- Synaptic protection in the brain of WldS mice occurs independently of age but is sensitive to gene-dose.PloS one · 2010Article
- Wld(S), Nmnats and axon degeneration--progress in the past two decades.Protein & cell · 2010Review
- Wallerian degeneration, wld(s), and nmnat.Annual review of neuroscience · 2010Review
- Expression of the neuroprotective slow Wallerian degeneration (WldS) gene in non-neuronal tissues.BMC neuroscience · 2009Article
- Molecular correlates of axonal and synaptic pathology in mouse models of Batten disease.Human molecular genetics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAltered neuronal vulnerability underlies many diseases of the human nervous system, resulting in degeneration and loss of neurons. The neuroprotective slow Wallerian degeneration (Wlds) mutation delays degeneration in axonal and synaptic compartments of neurons following a wide range of traumatic and disease-inducing stimuli, providing a powerful experimental tool with which to investigate modulation of neuronal vulnerability. Although the mechanisms through which Wlds confers neuroprotection remain unclear, a diverse range of downstream modifications, incorporating several genes/pathways, have been implicated. These include the following: elevated nicotinamide adenine dinucleotide (NAD) levels associated with nicotinamide mononucleotide adenylyltransferase 1 (Nmnat1; a part of the chimeric Wlds gene); altered mRNA expression levels of genes such as pituitary tumor transforming gene 1 (Pttg1); changes in the location/activity of the ubiquitin-proteasome machinery via binding to valosin-containing protein (VCP/p97); and modified synaptic expression of proteins such as ubiquitin-activating enzyme E1 (Ube1).
resultsWlds expression in mouse cerebellum and HEK293 cells induced robust increases in a broad spectrum of cell cycle-related genes. Both NAD-dependent and Pttg1-dependent pathways were responsible for mediating different subsets of these alterations, also incorporating changes in VCP/p97 localization and Ube1 expression. Cell proliferation rates were not modified by Wlds, suggesting that later mitotic phases of the cell cycle remained unaltered. We also demonstrate that Wlds concurrently altered endogenous cell stress pathways.
conclusionWe report a novel cellular phenotype in cells with altered neuronal vulnerability. We show that previous reports of diverse changes occurring downstream from Wlds expression converge upon modifications in cell cycle status. These data suggest a strong correlation between modified cell cycle pathways and altered vulnerability of axonal and synaptic compartments in postmitotic, terminally differentiated neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.